TScan Therapeutics (TCRX) Other Working Capital Changes (2020 - 2026)

TScan Therapeutics (TCRX) has 7 years of Other Working Capital Changes data on file, last reported at $16000.0 in Q1 2026.

• On a quarterly basis, Other Working Capital Changes fell 98.63% year-over-year to $16000.0 in Q1 2026; TTM through Mar 2026 was -$11.5 million, a 417.54% decrease from a year earlier, with the FY2025 full-year figure at -$10.3 million, down 648.91% from the prior year.
• Other Working Capital Changes for Q1 2026 stood at $16000.0, up from -$2.6 million in the prior quarter.
• Over the last five years, Other Working Capital Changes for TCRX reached as high as $1.2 million in Q1 2023 and fell as low as -$2.9 million in Q2 2023.
• Historically, Other Working Capital Changes has averaged $21294.1 across 5 years, with a median of $49000.0 in 2023.
• On a YoY basis, Other Working Capital Changes climbed as much as 92703.45% in 2023 and fell as far as 12396.77% in 2023.
• Year by year, Other Working Capital Changes stood at $4.9 million in 2022, then sank by 92.05% to $392000.0 in 2023, then surged by 928.06% to $4.0 million in 2024, then plunged by 163.7% to -$2.6 million in 2025, then surged by 100.62% to $16000.0 in 2026.
• Per Business Quant data, the three most recent Other Working Capital Changes figures were $16000.0 in Q1 2026, -$2.6 million in Q4 2025, and -$10.1 million in Q3 2025.